Review

You have full text access to this OnlineOpen article

Review and management of drug interactions with boceprevir and telaprevir†‡

  1. Jennifer J. Kiser1,§,*,
  2. James R. Burton2,
  3. Peter L. Anderson1,
  4. Gregory T. Everson2

Article first published online: 19 APR 2012

DOI: 10.1002/hep.25653

Issue

Hepatology

Hepatology

Volume 55, Issue 5, pages 1620–1628, May 2012

Additional Information

How to Cite

Kiser, J. J., Burton, J. R., Anderson, P. L. and Everson, G. T. (2012), Review and management of drug interactions with boceprevir and telaprevir. Hepatology, 55: 1620–1628. doi: 10.1002/hep.25653

Author Information

  1. 1

    Schools of Pharmacy, University of Colorado Denver, Aurora, CO

  2. 2

    Medicine, University of Colorado Denver, Aurora, CO

  1. §

    fax: 303-724-6135

*Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Anschutz Medical Campus, 12850 East Montview Boulevard, V20-C238, Aurora, CO 80045

  1. †

    Potential conflict of interest: Dr. Everson consults for, advises, and received grants from Vertex and Merck. Dr. Kiser received grants from Vertex and Merck.

  2. ‡

    This work was supported by National Institutes of Health K23 DK82321 (to J.J.K.)

  3. §

    fax: 303-724-6135

Publication History

  1. Issue published online: 19 APR 2012
  2. Article first published online: 19 APR 2012
  3. Accepted manuscript online: 13 FEB 2012 06:41AM EST
  4. Manuscript Accepted: 4 FEB 2012
  5. Manuscript Received: 19 DEC 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (789K)

Abstract

Boceprevir (BOC) and telaprevir (TPV), when added to pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the rates of sustained virologic response in treatment-naïve persons to approximately 70%. Though these agents represent an important advance in the treatment of chronic HCV, they present new treatment challenges to the hepatology community. BOC and TPV are both substrates and inhibitors of the hepatic enzyme, cytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes these agents to many drug interactions. Identification and appropriate management of potential drug interactions with TPV and BOC is critical for optimizing therapeutic outcomes during hepatitis C treatment. This review highlights the pharmacologic characteristics and drug-interaction potential of BOC and TPV and provides guidance on the management of drug interactions with these agents. (HEPATOLOGY 2012;)

View Full Article (HTML) Get PDF (789K)